SecBot SecBot
8-K ·Filed Jul 16, 2026

ABUS

Arbutus Biopharma Corp
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001171843-26-004708
8-K material event: Items 1.02
Actionable Insight ▲ Bullish

The $178M cash infusion and planned $230M buyback signal strong capital return potential. Monitor for the Genevant parent dividend in Q3 2026, which is a prerequisite for the buyback. The Pfizer/BioNTech lawsuits add significant upside optionality but are early-stage. Traders should watch for any updates on the contingent Moderna payment (up to $1.3B) tied to the 1498 appeal.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.74
T+0 close · Jul 16, 2026 · via day close
Latest settled
−10.97%
T+60 · $4.22
Vs SPY
−14.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 16 $4.74entry
  2. T+1 · 4mo ago −3.80%α −2.81% · $4.56
  3. T+5 · 4mo ago −5.70%α −4.03% · $4.47
  4. T+20 · 3mo ago −3.38%α −6.99% · $4.58
  5. T+60 · 6w ago −10.97%α −14.68% · $4.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arbutus received ~$178M from the Moderna settlement, filed three international patent lawsuits against Pfizer/BioNTech, and announced a plan to return up to ~$230M to shareholders via share repurchases in Q3 2026. The termination of the RSV agreement with Genevant is a minor procedural item with a $1M fee. The combination of a large cash infusion, ongoing litigation upside, and a substantial buyback plan is a clear positive catalyst.

Key Facts

  • Received approximately $178M as Arbutus' share of the $950M noncontingent Moderna settlement payment on July 8, 2026.
  • Filed three international patent infringement lawsuits (Canada, UPC) against Pfizer/BioNTech seeking injunctions and monetary damages.
  • Announced intent to return up to approximately $230M to shareholders via share repurchases, potentially including a modified Dutch Auction tender offer, expected to commence in Q3 2026 after receipt of a dividend from Genevant parent.
  • Terminated the RSV agreement with Genevant in exchange for a $1.0M termination fee.
  • CEO Lindsay Androski and CFO Tuan Nguyen received litigation-related cash bonuses tied to settlement proceeds (1.5% and 0.25% respectively).

Financial Impact

Arbutus received ~$178M in cash from the Moderna settlement, with potential for up to an additional $1.3B contingent payment and further proceeds from Pfizer/BioNTech litigation. The planned share repurchase of up to ~$230M represents ~25% of current market cap.

cashshareholder returnslitigation proceeds

Risk Factors

  • Contingent Moderna payment of up to $1.3B is subject to uncertain appeal outcomes and may never materialize.
  • Pfizer/BioNTech litigation is at an early stage; no guarantee of success or timeline.
  • Share repurchase plan is subject to board approval and receipt of dividend; may not occur as described.
  • Company is clinical-stage with no approved products; core business risk remains.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-004708
Exhibit: exh_101.htm0001171843-26-004708
Exhibit: exh_991.htm0001171843-26-004708
Document: 0001171843-26-004708-index-headers.html0001171843-26-004708
Document: 0001171843-26-004708-index.html0001171843-26-004708
Document: 0001171843-26-004708.txt0001171843-26-004708

Track record

25 reports on ABUS

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  3. Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
  4. Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
  5. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
  6. Nov 10, 20266d ago Press Release Neutral 4/10 No price data
  7. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
  8. Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  9. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  10. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 16, 2026